B
103.36
15.93 (18.22%)
| 前收盘价格 | 87.43 |
| 收盘价格 | 90.23 |
| 成交量 | 2,076,149 |
| 平均成交量 (3个月) | 657,450 |
| 市值 | 6,566,026,752 |
| 价格/销量 (P/S) | 12.97 |
| 股市价格/股市净资产 (P/B) | 18.39 |
| 52周波幅 | |
| 利润日期 | 13 Feb 2025 - 17 Feb 2025 |
| 营业毛利率 | -29.48% |
| 营业利益率 (TTM) | -38.21% |
| 稀释每股收益 (EPS TTM) | -2.09 |
| 季度收入增长率 (YOY) | 126.60% |
| 总债务/股东权益 (D/E MRQ) | 233.98% |
| 流动比率 (MRQ) | 3.32 |
| 营业现金流 (OCF TTM) | -242.15 M |
| 杠杆自由现金流 (LFCF TTM) | -101.52 M |
| 资产报酬率 (ROA TTM) | -14.97% |
| 股东权益报酬率 (ROE TTM) | -49.65% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Blueprint Medicines Corporation | 看涨 | 看涨 |
AIStockmoo 评分
2.5
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.50 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.89% |
| 机构持股比例 | 104.93% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lord, Abbett & Co. Llc | 30 Sep 2024 | 1,178,190 |
| Pictet Asset Management Holding Sa | 30 Sep 2024 | 1,166,507 |
| Polar Capital Holdings Plc | 30 Sep 2024 | 877,005 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 151.00 (Wells Fargo, 46.09%) | 购买 |
| 中 | 130.50 (26.26%) | |
| 低 | 88.00 (UBS, -14.86%) | 保留 |
| 平均值 | 128.00 (23.84%) | |
| 总计 | 7 购买, 1 保留 | |
| 平均价格@调整类型 | 92.93 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 135.00 (30.61%) | 购买 | 103.36 |
| 15 Nov 2024 | 135.00 (30.61%) | 购买 | 88.69 | |
| Wedbush | 13 Jan 2025 | 124.00 (19.97%) | 购买 | 103.36 |
| Stephens & Co. | 02 Jan 2025 | 140.00 (35.45%) | 购买 | 87.20 |
| JMP Securities | 09 Dec 2024 | 125.00 (20.94%) | 购买 | 94.57 |
| 18 Nov 2024 | 125.00 (20.94%) | 购买 | 90.18 | |
| HC Wainwright & Co. | 15 Nov 2024 | 135.00 (30.61%) | 购买 | 88.69 |
| 31 Oct 2024 | 135.00 (30.61%) | 购买 | 87.51 | |
| JP Morgan | 14 Nov 2024 | 126.00 (21.90%) | 购买 | 95.65 |
| Wells Fargo | 31 Oct 2024 | 151.00 (46.09%) | 购买 | 87.51 |
| UBS | 24 Oct 2024 | 88.00 (-14.86%) | 保留 | 83.09 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合